The TearCare® System, an interventional therapy that targets the leading cause of dry eye disease by directly treating Meibomian Gland Dysfunction (MGD)1, has reached a significant milestone with an established fee schedule from Novitas and First Coast. This coverage helps remove a critical barrier to effective dry eye care and could greatly improve patient access to this clinically proven treatment. 2-4
To receive the TearCare Medicare Reimbursement Guide, complete the form.
Recent Wins
The Medicare Advantage plans for Humana® and Highmark® have aligned their published fee schedules with Medicare guidelines in the Novitas and First Coast Medicare jurisdictions.
Turning Access into Care
- Millions of patients now have reimbursed access to in-office MGD therapy
- Improves patient access to a therapy proven clinically superior to leading dry eye prescription2-4
- Reduces a barrier tied to patient eye drop compliance
